Measurement of skin data of hyperpigmentation caused by chemotherapy with pyrimidine fluoride-derived anticancer agent for development of a medical cover foundation

Measurement of skin data of hyperpigmentation caused by chemotherapy with pyrimidine fluoride-derived anticancer agent for development of a medical cover foundation - Measurement of skin data of hyperpigmentation caused by chemotherapy with pyrimidine fluoride-derived anticancer agent

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022748

Enrollment

Registered

2016-06-15

Start date

2016-06-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer, colorectal cancer and esophageal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who have received pyrimidine fluoride-derived anticancer agent (S-1, capecitabine or 5-FU) more than one month. 2) Patients who have grade 2 "skin hyperpigmentation" in CTCAE Version 4.0. 3) PS of 0 or 1. 4) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients who are unable to respond to self-completed questionnaires. 2) Patients who are judged inappropriate for participate in this study by physician.

Design outcomes

Primary

Measure	Time frame
<Assessment by devices> 1) Optical properties (absorption and scattering coefficients) 2) Spectral reflectivity 3) Visia (Facial skin condition) 4) Epidermal and dermal water content <Self-completed questionnaires> Appearance-related distress	—

Countries

Japan

Contacts

Public ContactKeiko Nozawa

National Cancer Center Hospital Appearance Support Center

knozawa@ncc.go.jp03-3547-5201(3015)

Outcome results